AgingResearch.NewsJoin free

Geropharm

CompanyRussiaFounded 2001

RORWikidata

Geropharm develops one asset, in phase 1 (Memantinol in bioequivalence auc cmax pharmacokinetic). Mostly small molecule acting on GRIN2B, GRIN1 and GRIN2A; based in Russia, founded in 2001.

1
Asset
Furthest stage
Phase 1
6
Trials
0
Signals

Pipeline

1

  • Memantinol

    Uncompetitive NMDA receptor antagonist protecting against glutamate-induced excitotoxicity

    Phase 1, Small molecule, GRIN2B, GRIN1, bioequivalence auc cmax pharmacokinetic

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms4
  • Trials6
  • Similar companies6

Intelligence